Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Rd, Guangzhou, 510630, China.
Department of Medical Oncology, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Rd, Guangzhou, 510630, China.
Exp Cell Res. 2020 May 15;390(2):111968. doi: 10.1016/j.yexcr.2020.111968. Epub 2020 Mar 18.
EBV-associated gastric carcinoma (EBVaGC) is accompanied by massive lymphocyte infiltration, but therapy resistance and tumor progression still occur in patients with EBVaGC. Cancer stem cells (CSCs) are reported to possess immunomodulatory ability that allows them to resist immune-mediated rejection for many tumor types. However, whether and how CSCs in EBVaGC exhibit immunosuppression has not yet been elucidated. We isolated CSC-like sphere-forming cells (SFCs) from EBVaGC cell line SNU-719 using the cancer sphere method. We validated their CSC-associated properties in the expression of the epithelial-mesenchymal transition (EMT)-related genes, the ability to form colonies, and resistance to chemotherapy drug-induced apoptosis and explored their immunomodulatory ability using the coculture system with PBMC (peripheral blood mononuclear cell). These CSC-like SFCs were CD44CD24 and were more tumorigenic than the parental SNU-719 cells in the xenograft mouse model. Remarkably, in the tumor-PBMC co-culturing experiments, these EBVaGC SFCs demonstrated profound immunosuppression by inhibiting the proliferation of PBMCs and T cell activation as well as inducing the generation of regulatory T cells (Tregs). Furthermore, the induction of Tregs was partially dependent on prostaglandin E2 (PGE2) produced from SFCs. Moreover, the presence of high CD44CD24 cells in tumor tissues predicted a decreased disease-free survival in patients with EBVaGC. Our study collectively confirmed the existence and immune resistance of CSCs in EBVaGC and offers new insights into the development of novel anti-EBVaGC strategies by targeting CSCs.
EBV 相关胃癌(EBVaGC)伴有大量淋巴细胞浸润,但 EBVaGC 患者仍存在治疗抵抗和肿瘤进展。有报道称,癌症干细胞(CSCs)具有免疫调节能力,使它们能够抵抗多种肿瘤类型的免疫介导排斥。然而,EBVaGC 中的 CSCs 是否以及如何表现出免疫抑制作用尚未阐明。我们使用癌症球体方法从 EBVaGC 细胞系 SNU-719 中分离出 CSC 样球体形成细胞(SFC)。我们在表达上皮-间充质转化(EMT)相关基因、形成集落的能力以及对化疗药物诱导的细胞凋亡的抗性方面验证了它们的 CSC 相关特性,并使用与 PBMC(外周血单核细胞)的共培养系统探索了它们的免疫调节能力。这些 CSC 样 SFC 是 CD44CD24,在异种移植小鼠模型中比亲本 SNU-719 细胞具有更强的致瘤性。值得注意的是,在肿瘤-PBMC 共培养实验中,这些 EBVaGC SFC 通过抑制 PBMC 增殖和 T 细胞活化以及诱导调节性 T 细胞(Tregs)的产生来表现出显著的免疫抑制作用。此外,Treg 的诱导部分依赖于 SFC 产生的前列腺素 E2(PGE2)。此外,肿瘤组织中高 CD44CD24 细胞的存在预示着 EBVaGC 患者无病生存期缩短。我们的研究共同证实了 EBVaGC 中 CSCs 的存在和免疫抵抗,并为通过靶向 CSCs 开发新的抗 EBVaGC 策略提供了新的见解。